The drug developer has trials underway for treatments for Duchenne muscular dystrophy and Clostridium difficile infection.
Glyn Edwards, Summit’s chief executive, said: ”We applaud EURORDIS, the organisation representing rare disease patients in Europe, for bringing an annual spotlight to the plight of millions of people affected by rare diseases and in this year, recognising the immense impact that research is having and will continue to have for those living with rare diseases.”
“In the European Union a rare disease is defined as one that affects fewer than 5 in 10,000 of the general population, while in the United States, it is defined as a disease that affects fewer than 200,000 people.
“There are between 6,000 and 8,000 known rare diseases with around five new rare diseases described in the literature each week.
“Rare diseases are often chronic and life threatening and include rare conditions, such as childhood cancers, and some other well-known conditions including cystic fibrosis and DMD.”
Story by ProactiveInvestors